Dermatological Conditions

Chronic Spontaneous Urticaria (CSU) is defined as the spontaneous occurrence of itchy wheals (hives), swelling of the skin, or both lasting for at least 6 weeks. This study is testing a new treatment for CSU called ligelizumab. The purpose of this study is to evaluate the safety and effectiveness of ligelizumab in treating patients with chronic spontaneous urticaria.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Hidradenitis suppurativa is an inflammatory skin disease that affects gland-bearing skin in the axillae (armpit), in the groin and under the breasts. It is characterised by recurrent boil-like nodules and abscesses that end up in pus-like discharge, difficult-to-heal open wounds (sinuses) and scarring.

This study is testing a new treatment for moderate to severe hidradenitis suppurativa. The new treatment is an investigational drug called Risankizumab.

The purpose of this study is to assess the safety and efficacy of two different doses of Risankizumab compared to placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa. After week 16 of the trial all participants will receive the study drug at the same dose for the remainder of the trial. The study drug is not currently approved for use in Australia. The total length of this trial is up to 85 weeks. Both Risankizumab and the placebo are administered by an injection.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Alopecia areata (AA) is an autoimmune disease, meaning a person’s immune system mistakenly attacks their own body. Alopecia areata is characterised by hair loss in single or multiple areas of the scalp, face or body.

This research study is testing the effects of a study drug for patients with alopecia areata. This study will explore whether the study drug is safe and can help patients with alopecia areata regrow hair. The duration of the study is 26 months (just over 2 years). All participants in this study will receive the active study drug. The study drug is not currently approved for use in Australia.

Alopecia areata (AA) is an autoimmune disease, meaning a person’s immune system mistakenly attacks their own body. Alopecia areata is characterised by hair loss in single or multiple areas of the scalp, face or body.

This research study is testing the effects of a study drug for patients with alopecia areata. This study will explore whether the study drug is safe and can help patients with alopecia areata regrow hair. The duration of the study is 26 months (just over 2 years). All participants in this study will receive the active study drug. The study drug is not currently approved for use in Australia.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

The main aim of this study is to investigate the effectiveness of a new drug (ANAVEX 2-73) in treating early Alzheimer’s disease. Two clinical studies investigating use of ANAXVEX 2-73 in human subjects have been completed and have shown positive outcomes in cognition, such as memory, attention, speed of processing and reasoning and problem solving.

The current study extends on previous findings to further investigate the effect of this drug (including at varying dose levels) on cognitive and functional outcomes – the former being various aspects of thinking abilities and the latter being independence in completion of daily activities.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dementia

Research has shown a relationship between higher levels of brain iron, the presence of the Alzheimer’s protein, amyloid, and poorer memory and language skills. The purpose of this study is to test the effects of Deferiprone on your disease.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Palmoplantar pustulosis (PPP) is a skin condition that causes blister-like sores to show up on the palms of your hands and the soles of your feet. It can also cause cracked skin or reddened, scaly patches.

CSL324 is a new biological drug, a protein called an antibody. Antibodies are usually produced by special immune cells to fight infections (bacteria, viruses or other intruders into the body). The antibody CSL324 works by blocking the activity of a growth factor called “granulocyte-colony stimulating factor” which is responsible for stimulating the bone marrow to produce white blood cells and stem cells and release them into the bloodstream. Researchers believe this antibody may be able to help decrease inflammation in many inflammatory diseases such as PPP where white blood cells have been mobilised.

CSL324 is an experimental treatment. This means that it has not been approved for treating PPP by the Therapeutic Goods Administration in Australia.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Atopic dermatitis, often known as eczema, is a chronic, inflammatory skin disorder characterized by flaky skin lesions, intense itch, and a general deterioration in quality of life.

This research study is evaluating a new study drug called Lebrikizumab verses placebo. Both Lebrikizumab and the placebo are given every 2 weeks regularly as an injection under the skin, in patients with moderate to severe atopic dermatitis.

The purpose of this study is to assess the safety and efficacy of Lebrikizumab compared to placebo. The study drug is not currently approved for use in Australia. The duration of the study is 52 weeks.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4
Dermatological Conditions

Atopic dermatitis, often known as eczema, is a chronic, inflammatory skin disorder characterized by flaky skin lesions, intense itch, and a general deterioration in quality of life.

This research study is evaluating a new study drug called Nemolizumab, given regularly as an injection under the skin, in patients with moderate to severe atopic dermatitis not adequately controlled with topic corticosteroids. The purpose of this study is to assess the safety and efficacy of Nemolizumab compared to placebo.

The study drug is not currently approved for use in Australia. The duration of the study is 48 weeks with the opportunity to enrol in the long term extension study.

Trial phase 

check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4